Capricor Therapeutics Inc (CAPR)
5.13
+0.31
(+6.43%)
USD |
NASDAQ |
Apr 24, 13:53
Capricor Therapeutics Cash from Financing (TTM): 25.58M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 25.58M |
September 30, 2023 | 5.363M |
June 30, 2023 | 7.023M |
March 31, 2023 | 4.850M |
December 31, 2022 | 4.874M |
September 30, 2022 | 1.967M |
June 30, 2022 | 6.652M |
March 31, 2022 | 7.672M |
December 31, 2021 | 20.22M |
September 30, 2021 | 21.68M |
June 30, 2021 | 17.29M |
March 31, 2021 | 41.41M |
December 31, 2020 | 33.38M |
September 30, 2020 | 36.50M |
June 30, 2020 | 36.91M |
March 31, 2020 | 12.29M |
December 31, 2019 | 9.178M |
September 30, 2019 | 5.079M |
June 30, 2019 | 3.544M |
March 31, 2019 | 5.774M |
December 31, 2018 | 6.854M |
September 30, 2018 | 9.368M |
June 30, 2018 | 12.94M |
March 31, 2018 | 14.09M |
December 31, 2017 | 11.58M |
Date | Value |
---|---|
September 30, 2017 | 8.554M |
June 30, 2017 | 15.63M |
March 31, 2017 | 13.70M |
December 31, 2016 | 18.63M |
September 30, 2016 | 18.63M |
June 30, 2016 | 6.941M |
March 31, 2016 | 4.941M |
December 31, 2015 | 16.49M |
September 30, 2015 | 16.49M |
June 30, 2015 | 17.00M |
March 31, 2015 | 21.69M |
December 31, 2014 | 5.206M |
September 30, 2014 | 5.204M |
June 30, 2014 | 7.755M |
March 31, 2014 | 3.069M |
December 31, 2013 | 3.925M |
September 30, 2013 | 7.733M |
June 30, 2013 | 4.665M |
March 31, 2013 | 5.857M |
December 31, 2012 | 5.00M |
September 30, 2012 | 1.197M |
June 30, 2012 | 1.197M |
March 31, 2012 | 2.306M |
December 31, 2011 | 2.312M |
September 30, 2011 | 2.310M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.967M
Minimum
Sep 2022
41.41M
Maximum
Mar 2021
15.87M
Average
9.178M
Median
Dec 2019
Cash from Financing (TTM) Benchmarks
Cutera Inc | 89.53M |
Sarepta Therapeutics Inc | 125.00M |
PTC Therapeutics Inc | 646.40M |
Solid Biosciences Inc | 3.122M |
AIM ImmunoTech Inc | 0.485M |